ACC 2017: Disappointing Absorb Results Blamed On Implant Approach

Two-year results of the ABSORB III trial, comparing Abbott's Absorb bioresorbable stent to its Xience metal drug-eluting stent, showed a higher risk of target vessel failure with Absorb, prompting the US FDA to send-out a "Dear Doctor" letter reiterating the importance of following the recommended implantation technique.